Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
April 30, 2019

Faron says treatment for ARDS shows no improvement versus placebo

Faron Pharmaceuticals said clinical results from a study for the treatment of acute respiratory distress syndrome (ARDS) showed that the use of steroids appeared to worsen outcomes in several patients.

Faron Pharmaceuticals has said that clinical results from a study for the treatment of acute respiratory distress syndrome (ARDS) showed that the use of steroids appeared to worsen outcomes in several patients.

The company noted that treatment with Traumakine did not result in reduced mortality or an increased number of ventilator-free survival days when compared to placebo.

The placebo and Traumakine treatment groups were reported to be well balanced in basic demographics, except that the Traumakine group had more sepsis and less pneumonia as the etiology of ARDS when compared to the placebo group.

Faron said the post-hoc analysis revealed that the overall percentage of study subjects who received concomitant glucocorticoids was 77%, which was higher than that of the Interest study. The effect of glucocorticoids demonstrated the same trends to that observed from the Interest study.

“The use of steroids has become a standard in ARDS despite any evidence base and this requires critical reassessment.”

Additional sub-group analysis is not meaningful because of the limited trial size.

Faron Pharmaceuticals CEO Markku Jalkanen said: “As we had already observed in the Interest trial, it appears likely that corticosteroid use diminished the treatment benefit of Traumakine in ARDS patients in the Japanese Phase III study.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“Unfortunately, the use of steroids has become a standard in ARDS despite any evidence base and this requires critical reassessment, as the use of steroids appears to worsen outcomes in certain ARDS subgroups.”

Traumakine is currently under clinical investigations in ARDS and for the prevention of multi-organ failure after emergency aortic surgery.

ARDS is a serious, life-threatening medical condition characterised by widespread inflammation in the lungs and sudden failure of the respiratory system.

The UK’s Medicines and Healthcare Products Regulatory Agency has granted Promising Innovative Medicines designation for Traumakine, which is based on a patent-protected use of intra-venous interferon beta to prevent capillary leakage in organs under threat of ischemia and inflammation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU